Novozymes A/S (OTCMKTS:NVZMY) Sees Large Increase in Short Interest

Novozymes A/S (OTCMKTS:NVZMY) was the target of a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 26,584 shares, an increase of 87.2% from the June 30th total of 14,203 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 76,138 shares, the days-to-cover ratio is currently 0.3 days.

Analyst Upgrades and Downgrades

NVZMY has been the subject of several analyst reports. Kepler Capital Markets upgraded shares of Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Zacks Research upgraded Novozymes A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy”.

Novozymes A/S Stock Performance

Shares of Novozymes A/S stock traded down $1.07 during trading hours on Friday, reaching $64.76. The company’s stock had a trading volume of 6,002 shares, compared to its average volume of 74,611. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.03 and a current ratio of 1.67. The company’s 50 day simple moving average is $61.58 and its 200 day simple moving average is $60.45. Novozymes A/S has a one year low of $49.90 and a one year high of $66.82. The stock has a market cap of $26.85 billion, a P/E ratio of 43.76, a price-to-earnings-growth ratio of 2.97 and a beta of 0.92.

Novozymes A/S (OTCMKTS:NVZMY) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.51 earnings per share for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.31). Novozymes A/S had a return on equity of 6.52% and a net margin of 14.22%.The company had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.32 billion. As a group, analysts expect that Novozymes A/S will post 2.43 EPS for the current fiscal year.

About Novozymes A/S

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).